June 26, 2019
Acceleron expects top-line results in the Q1 2020 for Sotatercept in pulmonary arterial hypertension
Acceleron has completed target enrollment of patients with pulmonary arterial hypertension (PAH) in the PULSAR Phase 2 trial of sotatercept